Back to top
more

McKesson (MCK)

(Real Time Quote from BATS)

$606.84 USD

606.84
1,634,064

+57.53 (10.47%)

Updated Nov 7, 2024 03:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Here's Why Investors Should Hold Exact Sciences (EXAS) Stock

by Zacks Equity Research

Growth in Exact Sciences' (EXAS) legacy Screening business is attributable to Cologuard volume growth and contributions from the PreventionGenetics, Biomatrica and Oncoguard Liver products.

Stryker (SYK) Launches Q Guidance System for Spine Applications

by Zacks Equity Research

Stryker's (SYK) Q Guidance System is expected to be a procedural ecosystem for surgeons during guided spine surgery following its launch.

3 Reasons to Retain CONMED (CNMD) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.

Swayta Shah headshot

3 Stocks With Upgraded Broker Ratings for Impressive Returns

by Swayta Shah

As brokers have a deeper understanding of stocks, one must follow rating upgrades before investing. We select Hyatt Hotels (H), McKesson (MCK) and Carlsberg (CABGY) as these have seen rating upgrades recently.

PerkinElmer's (PKI) New Benchtop Platform to Boost Workflows

by Zacks Equity Research

PerkinElmer's (PKI) latest launch is expected to enable researchers to multiplex and perform immunophenotyping and viability assays in a lesser time with a simplified user interface.

Here's Why You Should Hold on to Surmodics (SRDX) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Boston Scientific (BSX) Benefits From New Buyouts, FX Woes Stay

by Zacks Equity Research

Boston Scientific's (BSX) organic growth performance is strong across all regions where most of its businesses are growing at the same pace or faster than their competitors in the respective markets.

Here's Why You Should Retain Integer Holdings (ITGR) Stock Now

by Zacks Equity Research

Integer Holdings (ITGR) continues to gain momentum from robust medical sales and a solid foothold in the broader MedTech space. However, intense competition persists.

The Zacks Analyst Blog Highlights McKesson, Corteva, Atmos Energy and National Fuel Gas

by Zacks Equity Research

McKesson, Corteva, Atmos Energy and National Fuel Gas are part of the Zacks top Analyst Blog.

3 Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio

by Zacks Equity Research

Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Here's Why Investors Should Hold Myriad Genetics (MYGN) Now

by Zacks Equity Research

Myriad Genetics' (MYGN) expansion across the globe, banking on myChoiceCDx test sales, seems impressive.

ResMed (RMD) Gains on Product Uptake Even as Expenses Rise

by Zacks Equity Research

The continued uptake of ResMed's (RMD) core non-invasive ventilation and life support ventilation solutions for COPD and neuromuscular disease is encouraging.

Here's Why You Should Hold on to OPKO Health (OPK) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.

Snehadri Nag headshot

4 Top-Ranked Defensive Stocks to Buy Amid Market Swings

by Snehadri Nag

Here we mention four defensive stocks, namely Corteva (CTVA), Atmos Energy, National Fuel Gas Company and McKesson with strong prospects to beat the market whims.

McKesson (MCK) Stock Moves -1.06%: What You Should Know

by Zacks Equity Research

McKesson (MCK) closed at $343.27 in the latest trading session, marking a -1.06% move from the prior day.

Derek Lewis headshot

3 Medical Stocks Displaying Remarkable Relative Strength in 2022

by Derek Lewis

In addition to favorable price action, all three carry a strong growth profile, making them appear even more enticing.

Stryker's (SYK) OptaBlate Tumor Ablation System Gets FDA Nod

by Zacks Equity Research

Stryker's (SYK) OptaBlate bone tumor ablation system is set to offer a reliable solution for people living with painful metastatic tumors.

Bruker (BRKR) Gains From New Product Bookings Amid Competition

by Zacks Equity Research

Bruker's (BRKR) revenue recognition from one gigahertz class NMR system and continued uptake of the timsTOF platform hold promise.

    Walgreens Boots' (WBA) Product Expansion Aids Amid Rivalry

    by Zacks Equity Research

    Sales contributions from Walgreens Boots' (WBA) newly-formed Walgreens Health segment instill investors' optimism.

    Here's Why Investors Should Retain Amedisys (AMED) Stock for Now

    by Zacks Equity Research

    Investors are optimistic about Amedisys' (AMED) better-than-expected earnings and notable buyouts.

    PerkinElmer's (PKI) Reagent Kit Receives FDA Clearance

    by Zacks Equity Research

    PerkinElmer's (PKI) T-Cell Select reagent kit is expected to allow for a more automated workflow following the FDA's approval.

    Is First Trust Consumer Staples AlphaDEX ETF (FXG) a Strong ETF Right Now?

    by Zacks Equity Research

    Smart Beta ETF report for FXG

    The Zacks Analyst Blog Highlights NextEra Energy, Southern Company, PepsiCo, Corteva and McKesson

    by Zacks Equity Research

    NextEra Energy, Southern Company, PepsiCo, Corteva and McKesson are included in this Analyst Blog.

    Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

    by Zacks Equity Research

    Investors are optimistic about QIAGEN's (QGEN) better-than-expected results and solid genomics uptake.